**Expeditied Partner Therapy**

**ABSTRACT:** Sexually transmitted infections (STIs) disproportionately affect women and create a preventable threat to their fertility. One factor that contributes to young women’s high rates of STIs is reinfection from an untreated sexual partner. One way to address this problem is through expedited partner therapy, the practice of treating the sexual partners of patients in whom STIs are diagnosed. Expedited partner therapy enables the obstetrician–gynecologist or other provider to give prescriptions or medications to patients to take to their partners without first examining these partners. Despite the effectiveness of expedited partner therapy, numerous legal, medical, practical, and administrative barriers hinder its routine use by obstetrician–gynecologists. The American College of Obstetricians and Gynecologists supports the use of expedited partner therapy as a method of preventing gonorrhea and chlamydial reinfection when a patient’s partners are unable or unwilling to seek medical care. Expedited partner therapy should be accompanied by patient counseling and written treatment instructions for the patient’s partner(s). Partners receiving expedited partner therapy should be encouraged to seek additional medical evaluation as soon as possible to discuss screening for other STIs, including human immunodeficiency virus (HIV) infection.

**Conclusions and Recommendations**

The American College of Obstetricians and Gynecologists (the College) makes the following conclusions and recommendations:

- The College supports the use of expedited partner therapy as a method of preventing gonorrhea and chlamydial reinfection when a patient’s partners are unable or unwilling to seek medical care.
- The College encourages members to advocate for the legalization of expedited partner therapy and to work with their health departments to develop protocols for its use.
- Partners receiving expedited partner therapy should be encouraged to seek additional medical evaluation as soon as possible to discuss screening for other sexually transmitted infections (STIs), including human immuno deficiency virus (HIV) infection.
- Expedited partner therapy is recommended only after an obstetrician–gynecologist or other provider has assessed the risk of intimate partner violence associated with partner notification. It is not intended for use in cases of suspected child abuse, sexual assault, or any other situation in which the patient’s safety from her abuser may be compromised.

**Background**

Sexually transmitted infections disproportionately affect women and create a preventable threat to their fertility. In the United States, adolescent girls and young women aged 15–24 years consistently have the highest number of cases of gonorrhea and chlamydial infection (1). One factor that contributes to young women’s high rates of STIs is reinfection from an untreated sexual partner. One way to address this problem is through expedited partner therapy, the practice of treating the sexual partners of patients in whom STIs are diagnosed. Expedited partner therapy enables the obstetrician–gynecologist or other provider to give prescriptions or
medications to patients to take to their partners without first examining these partners (2, 3).

It is preferable that partners undergo complete clinical evaluation, STI screening and HIV testing, counseling, and treatment by an obstetrician-gynecologist or other provider. However, when comprehensive medical management is not practical, the College supports the use of expedited partner therapy as a method of preventing gonorrhea and chlamydial reinfection when a patient’s partners are unable or unwilling to seek medical care. Evidence indicates that expedited partner therapy can decrease reinfection rates when compared with standard partner referrals for examination and treatment (2, 4). Although there are no data on the effectiveness of expedited partner therapy among women who have sex with women, expedited partner therapy may be an appropriate partner management option for same-sex partners of female patients. Data show that expedited partner therapy might have a role in partner management for trichomoniasis; however, no single partner management intervention has been shown to be more effective than any other in reducing trichomoniasis reinfection rates (3).

Barriers to Routine Use of Expedited Partner Therapy

Evidence suggests that the benefits of expedited partner therapy in preventing gonorrhea and chlamydial reinfection outweigh the risks of possible adverse effects of antibiotics, development of antibiotic resistance related to poor treatment adherence, or missed care opportunities (2). Despite the effectiveness of expedited partner therapy, numerous legal, medical, practical, and administrative barriers hinder its routine use by obstetrician-gynecologists. The Centers for Disease Control and Prevention (CDC) maintains a website (www.cdc.gov/std/EPT/legal/default.htm) with information about the legal status of expedited partner therapy in all 50 states and other jurisdictions (5). In the absence of a statute that expressly permits expedited partner therapy in all jurisdictions, obstetrician-gynecologists should rely on state or local legal counsel. The CDC and several state health departments have issued guidelines for practicing expedited partner therapy (2, 6–10), and its use has been endorsed by the College and other medical professional organizations (11–13). The state guidelines provide examples of expedited partner therapy documentation.

State child abuse reporting laws vary widely in terms of whether or not they require reporting the sexual activity of a minor or statutory rape as child abuse (14). This reporting requirement could reduce the likelihood that an adolescent will seek care and receive appropriate treatment. Expedited partner therapy is recommended only after the obstetrician–gynecologist or other provider has assessed the risk of intimate partner violence associated with partner notification. It is not intended for use in cases of suspected child abuse, sexual assault, or any other situation in which the patient’s safety from her abuser may be compromised.

Implementing Expedited Partner Therapy

In jurisdictions where expedited partner therapy is legally permitted, the College recommends the following principles for practice:

- Guidelines are subject to change, so clinicians should refer to CDC or state and local guidelines for the most up-to-date guidance on the provision of expedited partner therapy, including medications that are permissible and recommended for use (www.cdc.gov/std/epl/default.htm; www.cdc.gov/std/EPT/legal/default.htm).
- A patient’s sexual partners within the previous 2 months (or, if the patient had no partners in that time frame, the last partner) who are unable or unlikely to access medical services should be offered expedited partner therapy. Providing guidance on how the patient can inform her partner(s) about the infection can be helpful.
- Expedited partner therapy should be accompanied by patient counseling and written treatment instructions for the patient’s partner(s) (see www.cdc.gov/std/treatment/eplfinalreport2006.pdf).
- Partners receiving expedited partner therapy should be encouraged to seek additional medical evaluation as soon as possible to discuss screening for other STIs, including HIV infection.
- Patients should be instructed to abstain from sexual intercourse for 7 days after they and their sexual partners have completed treatment.
- A mechanism should be in place for patients and partners to report adverse events.
- Obstetrician–gynecologists or other providers should consult the regulations and policies for their jurisdiction to determine allowable reimbursement options and requirements for expedited partner therapy.

Advocacy

The College encourages members to advocate for the legalization of expedited partner therapy and to work with their health departments to develop protocols for its use. This involves active collaboration with stakeholders, including other health care providers, the state STI director, pharmacy and medical boards, and state medical societies. Obtaining an opinion or other ruling from the state medical and pharmacy boards indicating that expedited partner therapy is not unprofessional conduct may be easier than passing a new statute. However, a discrete statute expressly permitting expedited partner therapy provides the strongest legal authority.
Resources

The following resources are for information purposes only. Referral to these sources and websites does not imply the endorsement of the American College of Obstetricians and Gynecologists. These resources are not meant to be comprehensive. The exclusion of a source or website does not reflect the quality of that source or website. Please note that websites are subject to change without notice.


References


This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on www.acog.org or by calling the ACOG Resource Center.

While ACOG makes every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

All ACOG Committee members and authors have submitted a conflict of interest disclosure statement related to this published product. Any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. The ACOG policies can be found on acog.org. For products jointly developed with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product.